AbbVie announced it will acquire Capstan Therapeutics in a deal valued at up to $2.1 billion, marking a major step forward in its efforts to reshape immunology care through cutting-edge therapies. The acquisition includes Capstan’s novel in vivo CAR-T platform and its lead asset CPTX2309.
Haig Aghajanian, Co-Founder and Head of Research at Capstan Therapeutics, commented on the announcement on LinkedIn:
“Happy to share this news. Great for patients!”
The deal underscores AbbVie’s growing investment in next-generation treatments and highlights Capstan’s rapid rise as a key innovator in the field.
More posts featuring AbbVie.